Current preclinical studies have identified new potential targets for precision melanoma therapy, including CD126, chondroitin sulfate proteoglycan 4 (CSPG4), tandem CD70 and B7-H3, and αvβ3 integrin [14]. This evidence concerns the gene CD70 and melanoma.